LogicBio files registration for proposed IPO in the US

26th September 2018

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014

LONDON, 26 September 2018: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, announces that one of its Group Businesses, LogicBio Therapeutics Inc. (“LogicBio”), a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed initial public offering (“IPO”) in the United States of shares of its common stock . All shares to be sold in the offering will be offered by LogicBio. LogicBio plans to list its common stock on the NASDAQ Global Market under the ticker symbol “LOGC”. The number of shares to be sold and the price range per share for the proposed offering have not yet been determined.

The Registration Statement can be accessed through the SEC’s EDGAR Database. The registration statement relating to the shares of common stock has been filed with the SEC but has not yet become effective. The shares may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

A further announcement will be made in due course.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

The securities referred to in this release are to be offered only by means of a prospectus. When available, copies of the preliminary prospectus can be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com.